No Photo Available

Last Update

2016-10-23T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong Mazen Noureddin?

Dr. Mazen Noureddin

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Background Information

Employment History

Director of Fatty Liver Program

Cedars-Sinai Medical Center

Affiliations

Scientific Advisory Board Member
OWL Metabolomics

Education

MD

Web References (4 Total References)


Mazen Noureddin, MD Director ...

www.owlmetabolomics.com [cached]

Mazen Noureddin, MD Director of Fatty Liver Program at Cedars-Sinai Medical Center


OWL > Management team > ...

www.owlmetabolomics.com [cached]

OWL > Management team > Mazen Noureddin, MD

OWL
...
Mazen Noureddin, MD
Mazen Noureddin, MD, is the Director of Fatty Liver Program at Cedars-Sinai Medical Center with a focus on translational research, particularly in nonalcoholic fatty liver disease (NAFLD). Dr. Noureddin has conducted investigational, translational and clinical studies of novel treatments for nonalcoholic steatohepatitis (NASH). One the pathogenesis pathways that he is currently investigating is the role of S-adenosylmethionine (SAMe) in NAFLD/NASH.
Dr. Noureddin began working on hepatic SAMe during his internal medicine residency at the University of Southern California (USC) in the laboratory of Shelly Lu, MD.
...
After his NIH fellowship, Dr. Noureddin embarked on a two-year gastroenterology fellowship at the University of California, San Diego, where he focused on NAFLD and NASH and assessing the clinical utility of a new liver-imaging technique, MRI-proton density fat fraction (MRI-PDFF). This scanning methodology is currently considered the new reference standard for the imaging of fatty liver in NAFLD patients.
Dr. Noureddin returned to the University of Southern California (USC) and established their fatty liver program to continue research on NAFLD/NASH, while conducting translational research and clinical trials. Subsequently, Dr. Noureddin teamed up with Cedars-Sinai in 2015 to establish the Cedars-Sinai Fatty Liver Program. He is currently active in a number of clinical studies investigating new drug treatments for NASH, researching the translational pathogenesis of NAFLD/NASH and is involved in novel liver biomarker research & development.


· Mazen Noureddin, MD, is ...

www.owlmetabolomics.com [cached]

· Mazen Noureddin, MD, is the Director of Fatty Liver Program at Cedars-Sinai Medical Center with a focus on translational research, particularly in nonalcoholic fatty liver disease (NAFLD). Dr. Noureddin has conducted investigational, translational and clinical studies of novel treatments for nonalcoholic steatohepatitis (NASH) and helped to validate a new liver-imaging technique, MRI-proton density fat fraction (MRI-PDFF).

Dr. Noureddin completed his hepatology fellowship at the National Institutes of Health (NIH) and is presently active in a number of clinical studies investigating new drug treatments for NASH, researching the translational pathogenesis of NAFLD/NASH and is deeply enganged in novel liver biomarker R&D.


· Mazen Noureddin, MD, is ...

www.owlmetabolomics.com [cached]

· Mazen Noureddin, MD, is the Director of Fatty Liver Program at Cedars-Sinai Medical Center with a focus on translational research, particularly in nonalcoholic fatty liver disease (NAFLD). Dr. Noureddin has conducted investigational, translational and clinical studies of novel treatments for nonalcoholic steatohepatitis (NASH) and helped to validate a new liver-imaging technique, MRI-proton density fat fraction (MRI-PDFF).

Dr. Noureddin completed his hepatology fellowship at the National Institutes of Health (NIH) and is presently active in a number of clinical studies investigating new drug treatments for NASH, researching the translational pathogenesis of NAFLD/NASH and is deeply enganged in novel liver biomarker R&D.

Similar Profiles

Other People with this Name

Other people with the name Noureddin

Mazen Noureddin
Medical Group Of Beverly Hills Inc

Ali Noureddin
FirstService Corporation

Marwa Noureddin
American University of Beirut

Sina Noureddin
App Annie Limited

Hisham Ahmed Mohamed Amin Noureddin
TE Data

City Directory Icon

Browse ZoomInfo's Business Contact Directory by City

People Directory Icon

Browse ZoomInfo's
Business People Directory

Company Directory Icon

Browse ZoomInfo's
Advanced Company Directory